Hiroaki Wakimoto

Harvard University — United States

Medicine · Health Sciences

70h-index19.8kcitations636works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(162), Virus-based gene therapy research(139), Cancer, Hypoxia, and Metabolism(85), Cancer Research and Treatments(79), CAR-T cell therapy research(71)

Publications633 total

Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles
Acta Neuropathologica·2026
A nanobody-stem cell platform targeting innate and adaptive immune axis in the tumour microenvironment
EBioMedicine·2026Open Access
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells
Nature Chemical Biology·2026
Local therapy with hypoxia-targeting radiopharmaceutical [64Cu]Cu-ATSM in high-grade glioma patient-derived xenograft models
Radiotherapy and Oncology·2025
10166-CB-4 Evaluation of Radiation Response and 2-Hydroxyglutarate Suppression by IDH Inhibition in IDH Mutant Glioma Cells
Neuro-Oncology Advances·2025Open Access
Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
Acta Neuropathologica Communications·2025Open Access
TMOD-16. Generation of orthotopic patient-derived xenografts from progressive oligodendroglioma without TMZ-induced hypermutation
Neuro-Oncology·2025
EXTH-58. Long-term treatment with mutant IDH inhibitor DS-1001b suppresses tumor growth and induces epigenetic reprogramming in IDH1-mutant gliomas
Neuro-Oncology·2025Open Access
DDDR-71. Dual inhibition of RAF/MEK and FAK signaling improves survival in intracranial meningioma models
Neuro-Oncology·2025Open Access
EXTH-57. Evaluation of a novel CNS penetrant YAP/TEAD-targeted therapy for lung cancer brain metastases
Neuro-Oncology·2025
EXTH-47. Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells
Neuro-Oncology·2025Open Access
DDDR-60. Investigating CDK2 and CDK4 Inhibition in IDH-Mutant Glioma with CDKN2A Deletion
Neuro-Oncology·2025Open Access
EXTH-45. Oncolytic Herpes Simplex Virus Synergizes with DNA-PKcs Inhibitors to Treat Glioblastoma
Neuro-Oncology·2025Open Access
DDDR-34. Bcl-xL inhibition enhances the efficacy of Temozolomide by targeting senescent glioblastoma cells
Neuro-Oncology·2025Open Access
EXTH-91. Leveraging the cGAS-STING pathway to modulate the tumor microenvironment and enhance immunotherapies in glioblastoma
Neuro-Oncology·2025Open Access
SUV-max of 68Ga-DOTATATE PET/CT correlates with WHO grade and RNA risk classification in meningioma
Journal of Neuro-Oncology·2025
Emerging targeted therapies in meningiomas
Current Opinion in Neurology·2025
Signal Amplification for Fluorescent Staining of Single Particles in Liquid Biopsies: Circulating Tumour Cells and Extracellular Vesicles
Journal of Extracellular Vesicles·2025· 1 citedOpen Access
Molecular landscape and clinical correlates of olfactory groove meningiomas: a multi-institutional study
Journal of neurosurgery·2025
Photodynamic therapy using talaporfin sodium and semiconductor laser induces dose and time dependent cytocidal effect for human glioma derived stem cells
Photodiagnosis and Photodynamic Therapy·2025Open Access
page 1 of 32Next →

Frequent Co-authors

Daniel P. Cahill(15), William T. Curry(11), David N. Louis(10), Mario L. Suvà(9), Samuel D. Rabkin(8), Robert L. Martuza(8), Priscilla K. Brastianos(7), Anoop P. Patel(7), Khalid Shah(7), Brian V. Nahed(6), Tracy T. Batchelor(6), Orit Rozenblatt–Rosen(6), Aviv Regev(6), B Bernstein(6), Itay Tirosh(6), S. Andrew(6), Shawn Gillespie(5), A. John Iafrate(4), E. Antonio Chiocca(4), Toshiro Hara(3)